Oppenheimer upgraded ArriVent BioPharma to "outperform" with a $39 price target, indicating a 39.39% upside.
Oppenheimer has upgraded its rating for ArriVent BioPharma (NASDAQ: AVBP) to "outperform," raising the price target from $35.00 to $39.00, indicating a potential 39.39% upside. Goldman Sachs also increased its target from $28.00 to $38.00, while HC Wainwright raised its target to $36.00. Most analysts rate the stock as a "buy," and institutional ownership stands at 9.48%. The company focuses on developing targeted cancer therapies.
September 10, 2024
6 Articles